5
Views
0
CrossRef citations to date
0
Altmetric
Review Article

Bone Mineral Density in Male Schizophrenia Patients: A Review

&
Pages 43-48 | Published online: 04 Dec 2011

References

  • Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT, Jr., Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S: Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161(8):1334–1349
  • Meyer JM, Nasrallah HA eds. Medical Illness and Schizophrenia. Washington, D.C.: American Psychiatric Press, Inc., 2003
  • NIH: Consensus Conference development panel on osteoporosis prevention, diagnosis and therapy. JAMA 2001; 285:785–795
  • Barondess DA, Nelson DA: Schlaen SE: Whole body bone, fat, and lean mass in black and white men. J Bone Miner Res 1997; 12(6):967–971
  • Wagner DR, Heyward VH: Measures of body composition in blacks and whites: A comparative review [see comment]. Am J Clini Nutr 2000; 71(6):1392–1402
  • Naidoo U, Goff DC, Klibanski A: Hyperprolactinemia and bone mineral density: The potential impact of antipsychotic agents. Psychoneuroendocrinology 2003; 28(Suppl 2):97–108
  • Delva NJ, Crammer JL, Jarzylo SV, Lawson JS, Owen JA, Sribney M, Weir BJ, Yendt ER: Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia. Biol Psychiatry 1989; 26(8):781–793
  • Tannirandorn P, Epstein S: Drug-induced bone loss. Osteoporosis Intl 2000; 11(8):637–659
  • Cohen O, Rais T, Lepkifker E, Vered I: Lithium carbonate therapy is not a risk factor for osteoporosis. Horm Met Res 1998; 30(9):594–597
  • Fric M, Laux G: Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics. Psychiatrische Praxis 2003; 30(Suppl 2):S97–101
  • Biller BM, Baum HB, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A: Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea [see comments]. J Clin Endocrinol Metab 1992; 75(3):692–697
  • Abraham G, Paing WW, Kaminski J, Joseph A, Kohegyi E, Josiassen RC: Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: A prospective study. Am J Psychiatry 2003; 160(9):1618–1620
  • Higuchi T, Komoda T, Sugishita M, Yamazaki J, Miura M, Sakagishi Y, Yamauchi T: Certain neuroleptics reduce bone mineralization in schizophrenic patients. Neuropsychobiology 1987; 18(4):185–188
  • Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y, Rosan R: Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995; 57(5):485–491
  • Abraham G, Friedman RH, Verghese C: Osteoporosis demonstrated by dual energy x-ray absorptiometry in chronic schizophrenic patients. Biol Psychiatry 1996; 40(5):430–431
  • Crawford AM, Beasley CM, Jr., Tollefson GD: The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997; 26(1):41–54
  • Bilici M, Cakirbay H, Guler M, Tosun M, Ulgen M, Tan U: Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 2002; 112(7):817–828
  • Abraham G, Halbreich U, Friedman RH, Josiassen RC: Bone mineral density and prolactin associations in patients with chronic schizophrenia [see comment]. Schizophr Res 2003; 59(1):17–18
  • Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M: Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clini Psychiatry 2003; 64(7):761–766
  • Meaney AM, O–Keane V: Reduced bone mineral density in patients with schizophrenia receiving prolactin raising antipsychotic medication. J Psychopharmacology 2003; 17(4):455–458
  • Lean M, De Smedt G: Schizophrenia and osteoporosis. Int Clini Psychopharmacol 2004; 19:31–35
  • Meaney AM, Smith S, Howes OD, O–Brien M, Murray RM, O–Keane V: Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004; 184:503–508
  • Lehman D, Meyer JM: Decreased bone mineral density in male schizophrenia patients. Schizophr Res 2005; 76:131–133
  • Combs DR, Advokat C: Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia. Schizophr Res 2000; 46(2–3):129–137

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.